Shilpa Medicare Ltd has received US Food and Drug Administration approval for its ANDA, Busulfan Injection, 60 mg/10 mL on 18.04.2019.
Busulfan Injection, 60 mg/lO mL is a generic equivalent of reference listed drug (RLD), Busulfex Injection, 60 mg/10 mL, used in the treatment of patients with chronic myelogenous leukemia as recommended in the label approved by FDA.
According to IQVIA MAT Q4 2018 data, the US market for Busulfan Injection, 6O mg/1O mL is approximately US$ 32.8 Million.
Shares of SHILPA MEDICARE LTD. was last trading in BSE at Rs.398.7 as compared to the previous close of Rs. 376.2. The total number of shares traded during the day was 8092 in over 838 trades.
The stock hit an intraday high of Rs. 414.75 and intraday low of 360.9. The net turnover during the day was Rs. 3141860.